The U.S. Food and Drug Administration approved Nereus (tradipitant) from Vanda Pharmaceuticals, marking the first new pharmaceutical for motion sickness in more than four decades. Approval was supported by three pivotal clinical studies, including two phase III trials conducted in real‑world boat settings. Vanda plans an early‑2026 launch and the label covers prevention of motion‑induced vomiting. Investors reacted immediately: Vanda shares spiked intraday after the announcement, reflecting the perceived commercial upside for a broadly applicable symptomatic therapy. The program’s regulatory win also resets comparators in neurokinin‑1 receptor–based symptom management and could influence development plans for competing antiemetic agents. Clinical details and trial endpoints were cited in the approval notice and company statements.